D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 13.54 USD 0.89% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Day One Biopharmaceuticals Inc?
Write Note

Intrinsic Value

DAWN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one DAWN stock under the Base Case scenario is 18.62 USD. Compared to the current market price of 13.54 USD, Day One Biopharmaceuticals Inc is Undervalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DAWN Intrinsic Value
18.62 USD
Undervaluation 27%
Intrinsic Value
Price
D
Base Case Scenario

Valuation Backtest
Day One Biopharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DAWN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DAWN?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Day One Biopharmaceuticals Inc

Provide an overview of the primary business activities
of Day One Biopharmaceuticals Inc.

What unique competitive advantages
does Day One Biopharmaceuticals Inc hold over its rivals?

What risks and challenges
does Day One Biopharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Day One Biopharmaceuticals Inc recently?

Summarize the latest earnings call
of Day One Biopharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Day One Biopharmaceuticals Inc.

Provide P/S
for Day One Biopharmaceuticals Inc.

Provide P/E
for Day One Biopharmaceuticals Inc.

Provide P/OCF
for Day One Biopharmaceuticals Inc.

Provide P/FCFE
for Day One Biopharmaceuticals Inc.

Provide P/B
for Day One Biopharmaceuticals Inc.

Provide EV/S
for Day One Biopharmaceuticals Inc.

Provide EV/GP
for Day One Biopharmaceuticals Inc.

Provide EV/EBITDA
for Day One Biopharmaceuticals Inc.

Provide EV/EBIT
for Day One Biopharmaceuticals Inc.

Provide EV/OCF
for Day One Biopharmaceuticals Inc.

Provide EV/FCFF
for Day One Biopharmaceuticals Inc.

Provide EV/IC
for Day One Biopharmaceuticals Inc.

Show me price targets
for Day One Biopharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Day One Biopharmaceuticals Inc?

How accurate were the past Revenue estimates
for Day One Biopharmaceuticals Inc?

What are the Net Income projections
for Day One Biopharmaceuticals Inc?

How accurate were the past Net Income estimates
for Day One Biopharmaceuticals Inc?

What are the EPS projections
for Day One Biopharmaceuticals Inc?

How accurate were the past EPS estimates
for Day One Biopharmaceuticals Inc?

What are the EBIT projections
for Day One Biopharmaceuticals Inc?

How accurate were the past EBIT estimates
for Day One Biopharmaceuticals Inc?

Compare the revenue forecasts
for Day One Biopharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Day One Biopharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Day One Biopharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Day One Biopharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Day One Biopharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Day One Biopharmaceuticals Inc with its peers.

Analyze the financial leverage
of Day One Biopharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Day One Biopharmaceuticals Inc.

Provide ROE
for Day One Biopharmaceuticals Inc.

Provide ROA
for Day One Biopharmaceuticals Inc.

Provide ROIC
for Day One Biopharmaceuticals Inc.

Provide ROCE
for Day One Biopharmaceuticals Inc.

Provide Gross Margin
for Day One Biopharmaceuticals Inc.

Provide Operating Margin
for Day One Biopharmaceuticals Inc.

Provide Net Margin
for Day One Biopharmaceuticals Inc.

Provide FCF Margin
for Day One Biopharmaceuticals Inc.

Show all solvency ratios
for Day One Biopharmaceuticals Inc.

Provide D/E Ratio
for Day One Biopharmaceuticals Inc.

Provide D/A Ratio
for Day One Biopharmaceuticals Inc.

Provide Interest Coverage Ratio
for Day One Biopharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Day One Biopharmaceuticals Inc.

Provide Quick Ratio
for Day One Biopharmaceuticals Inc.

Provide Current Ratio
for Day One Biopharmaceuticals Inc.

Provide Cash Ratio
for Day One Biopharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Day One Biopharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Day One Biopharmaceuticals Inc?

What is the current Free Cash Flow
of Day One Biopharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Day One Biopharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Day One Biopharmaceuticals Inc

Current Assets 581m
Cash & Short-Term Investments 558.4m
Receivables 8.7m
Other Current Assets 13.9m
Non-Current Assets 19.8m
Long-Term Investments 117k
PP&E 3.5m
Intangibles 16.2m
Current Liabilities 39.7m
Accounts Payable 3m
Accrued Liabilities 30.8m
Other Current Liabilities 6m
Non-Current Liabilities 5.6m
Other Non-Current Liabilities 5.6m
Efficiency

Earnings Waterfall
Day One Biopharmaceuticals Inc

Revenue
102m USD
Cost of Revenue
-2.3m USD
Gross Profit
99.7m USD
Operating Expenses
-311.1m USD
Operating Income
-211.5m USD
Other Expenses
127.2m USD
Net Income
-84.3m USD

Free Cash Flow Analysis
Day One Biopharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DAWN Profitability Score
Profitability Due Diligence

Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

DAWN Solvency Score
Solvency Due Diligence

Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DAWN Price Targets Summary
Day One Biopharmaceuticals Inc

Wall Street analysts forecast DAWN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DAWN is 37.74 USD with a low forecast of 28.28 USD and a high forecast of 50.4 USD.

Lowest
Price Target
28.28 USD
109% Upside
Average
Price Target
37.74 USD
179% Upside
Highest
Price Target
50.4 USD
272% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DAWN?

Click here to dive deeper.

Dividends

Day One Biopharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DAWN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DAWN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Day One Biopharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.4B USD

Dividend Yield

0%

Description

Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in South San Francisco, California and currently employs 42 full-time employees. The company went IPO on 2021-05-27. The company is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. The company seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. The company has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.

Contact

CALIFORNIA
South San Francisco
395 Oyster Point Blvd Ste 217
+12069134300.0
dayonebio.com

IPO

2021-05-27

Employees

42

Officers

CEO, President & Director
Dr. Jeremy Bender M.B.A., Ph.D.
Co-Founder and Head of R&D
Dr. Samuel C. Blackman M.D., Ph.D.
COO, CFO & Secretary
Mr. Charles N. York II, M.B.A.
General Counsel and Chief Compliance Officer
Mr. Adam Dubow
Chief Technology Officer
Mr. John Stubenrauch Ph.D.
Chief People Officer
Ms. Jaa Roberson
Show More
Chief Development Officer
Dr. Davy Chiodin Ph.D., Pharm.D.
Chief Commercial Officer
Ms. Lauren Merendino M.B.A.
Chief Medical Officer
Dr. Elly Barry M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one DAWN stock?

The intrinsic value of one DAWN stock under the Base Case scenario is 18.62 USD.

Is DAWN stock undervalued or overvalued?

Compared to the current market price of 13.54 USD, Day One Biopharmaceuticals Inc is Undervalued by 27%.

Back to Top